Research programme: type-I interferons - Alios BioPharma

Drug Profile

Research programme: type-I interferons - Alios BioPharma

Alternative Names: Beta-Gly; Glycoferon; Hyperglycosylated type I interferons - Alios BioPharma; Oncoferon

Latest Information Update: 10 Nov 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alios BioPharma
  • Class Interferons
  • Mechanism of Action Interferon type I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Hepatitis C; Malignant melanoma; Multiple sclerosis

Most Recent Events

  • 07 Nov 2014 Alios BioPharma has been acquired by Johnson & Johnson
  • 11 Mar 2011 Preclinical development is ongoing in USA
  • 03 Nov 2009 Pharmacokinetic and pharmacodynamic data from preclinical trials presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top